PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Go back to PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy| PTC THERAPEUTICS (NASDAQ: PTCT) | Delayed: 65.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.96 | 52 Week High | $35.40 | |||
| Open | $65.96 | 52 Week Low | $4.03 | |||
| Day High | $65.96 | P/E | 7.02 | |||
| Day Low | $65.96 | EPS | $9.40 | |||
| Volume | 147,733 | |||||
